by Review

July 22, 2020

(HealthDay)—Use of pembrolizumab is supported among patients with advanced melanoma, regardless of BRAF V600E/K mutation status or prior receipt of a BRAF inhibitor (BRAFi) with or without MEK inhibitor (MEKi) therapy, according to a study published online July 20 in JAMA Oncology.

This post was originally published on this site

About the author 

Review

Leave a Reply

{"email":"Email address invalid","url":"Website address invalid","required":"Required field missing"}

Title Goes Here


Get this Free E-Book

Use this bottom section to nudge your visitors.